Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate for Chemotherapy-Induced Peripheral Neurotoxicity in Breast Cancer
NCT05813145Completed
- Sponsor
- Damanhour University
- Start
- Jan 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing Placebo Group with Fenofibrate Group (2 arms). Primary endpoints: Nerve Growth Factor Concentration at 3 months and Neurofilament Light Chain Protein Concentration at 3 months. Started Jan 2023; status: completed.
02
Drugs
fenofibrate
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05813145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813145.